Alan Lotvin, M.D.

Executive Vice President and Chief Transformation Officer, CVS Health
Alan Lotvin

Alan Lotvin leads the company’s specialty pharmacy business. He is focused on driving specialty pharmacy strategy and identifying opportunities for growth and innovation. He is a published author with an extensive clinical background and experience in the health care services, pharmaceutical benefit management and specialty pharmacy industries. Lotvin began his career as an interventional cardiologist in the New York metropolitan area with a faculty appointment at College of Physicians and Surgeons at Columbia University.

Lotvin holds a Master’s degree in Medical Informatics from Columbia University and a medical degree from the State University of New York Health Sciences Center in Brooklyn.

Featured Insights by this contributor

Alan Lotvin, M.D. explains data's role in transforming the consumer health care experience
Pharmacy Innovation
CVS Health is using data to improve health outcomes, lower costs, and transform the consumer's health care experience. More
Video
Portrait photo of Jon Roberts speaking at the 2018 CVS Health Forum
Specialty
Learn more about how CVS Health plans to reshape kidney care by helping improve care and quality of life for patients with kidney disease. More
Video
Middle-aged couple in front of cafe window
Specialty
CVS Health is utilizing our integrated model and expertise in holistic patient care to an area of unmet clinical need — chronic kidney disease and end-stage renal disease – to... More
Feature
Specialty pharmaceutical and treatment landscape is evolving and requires the right trend management. More
Programs & Services Video
Icon of syringe, infusion bag and dollar sign tag
Specialty
The specialty pharmaceutical market continues to grow as a percentage of the overall prescription drug market, and its impact on payor trend also is rising. More
Feature
Icon of infusion bag and dollar bills
Specialty
Specialty spend under medical benefit is growing and a comprehensive medical benefit management strategy can help ensure appropriate utilization and control costs More
Feature
Icon of syringe and pills
Specialty
After a 19-year high for new drug approvals in 2015, 2016 saw a sharp decline. Including the six new biologics approved by the Center for Biologics Evaluation and Research (CBER... More
Feature
Pills and female pharmacist icon
Specialty
The impact of specialty medications on payors’ trend is not only rising, it is doing so more rapidly than ever before. From 2010 to 2015, spending on specialty drugs doubled,... More
Feature